NEW YORK – Antibody analysis firm Serimmune said on Friday that it has entered an agreement with biotech company Atreca around development of therapeutic antibodies for cancer.
Under the agreement, Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.
The SERA platform uses a combination of bacterial display peptide libraries, next-generation sequencing, and machine learning to identify antigens involved in antibody response.